Search results for "228"

showing 10 items of 834 documents

Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis

2016

Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone …

Adultmedicine.medical_specialtyHydrocarbons Fluorinatedintranasal corticosteroidmedicine.drug_classmedicine.medical_treatmentImmunologynasal sprayAnti-asthmatic AgentMedication Adherence03 medical and health sciencesnasal aerosol0302 clinical medicineQuality of lifeNasal AerosolmedicineAnimalsHumansImmunology and AllergyAnti-Asthmatic AgentsChild030223 otorhinolaryngologyintranasal corticosteroidsAsthmaallergic rhinitisbusiness.industryRespiratory diseaseBeclomethasoneNasal Spraysasthmamedicine.diseaseRhinitis AllergicDermatologyBeclomethasone dipropionate hydrofluoroalkaneAerosol Propellants030228 respiratory systemNasal sprayinflammationQuality of LifeCorticosteroidNasal administrationbusinessallergic rhiniti
researchProduct

Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study

2021

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a clinical entity with specific features that impacts significantly on patient quality of life (QoL). CRSwNP is often associated with asthma and is difficult to control and manage despite pharmacological and/or surgical treatment. Omalizumab, a monoclonal anti-IgE antibody, has emerged as a putative therapeutic option. Objective To evaluate the effects of omalizumab on nasal polyp (NP) size and QoL assessed by Sino-Nasal Outcome Test-22 (SNOT-22) in patients with recalcitrant CRSwNP and mild asthma. Methods A multicenter retrospective analysis of patient data from the Community of Valencia (Spain) was performed. Adult patients …

Adultmedicine.medical_specialtyMild asthmaOmalizumabOmalizumabaspirin-exacerbated respiratory diseasechronic rhinosinusitis with nasal polypsImmunoglobulin E03 medical and health sciencesNasal Polyps0302 clinical medicineQuality of lifeSNOT-22Internal medicinemedicineHumansImmunology and AllergyNasal polypsIn patient030223 otorhinolaryngologyRetrospective StudiesRhinitisnasal polypsbiologybusiness.industrytotal nasal endoscopic polyp scoreRetrospective cohort studyGeneral Medicinemedicine.diseaseAsthmaTreatment Outcomequality of lifetissue eosinophilia030228 respiratory systemOtorhinolaryngologyIgE SNOT-22 aspirin-exacerbated respiratory disease chronic rhinosinusitis with nasal polyps mild asthma nasal polyps omalizumab quality of life tissue eosinophilia total nasal endoscopic polyp scoreChronic DiseaseQuality of Lifebiology.proteinomalizumabAspirin exacerbated respiratory diseaseIgEbusinessmild asthmamedicine.drugAmerican Journal of Rhinology & Allergy
researchProduct

Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion

2021

International audience; Severe asthma often remains uncontrolled despite effective treatments and evidence-based guidelines. A group of global experts in asthma and biologic medications from nine countries considered the most relevant clinical variables to manage severe asthma in adult patients and guide treatment choice. The resulting recommendations address the investigation of biomarker levels (blood eosinophil count along with fractional concentration of exhaled nitric oxide [FeNO]), clinical features (oral corticosteroid [OCS] dependency, specific comorbid disease entities associated with severe type 2 asthma), and safety considerations. Current evidence suggests that biomarkers, inclu…

Adultsevere asthmamedicine.medical_specialty[SDV]Life Sciences [q-bio]Nitric Oxide[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Health caremedicineImmunology and AllergyHumans[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyIntensive care medicineExpert TestimonyAsthmaBiological Productsalgorithmbusiness.industrymedicine.diseaseAsthma3. Good healthClinical trialClinical research030228 respiratory systemExhalation030220 oncology & carcinogenesisExhaled nitric oxide[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractBiomarker (medicine)Sputumeosinophilsmedicine.symptombusiness[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology
researchProduct

Specific challenges in end-of-life care for patients with hematological malignancies.

2019

Purpose of review The disease-related burden of patients with hematological malignancies is comparable with patients suffering from solid tumors. Palliative care offers relief from suffering independent of type of disease and prognosis. The prevalence of hematological malignancies is expected to increase in the next 20 years because of better therapeutic options with longer survival and because of the aging population. However, patients with hematological malignancies are underrepresented in palliative care as these diseases are associated with special care needs and prognostic uncertainty, which differ from the unambiguity of terminally ill patients with solid tumors. This review describes…

Advance care planningmedicine.medical_specialtyPalliative caremedicine.medical_treatmentHealth StatusMEDLINEHematopoietic stem cell transplantationDiseaseComorbidityCritical Care and Intensive Care Medicine03 medical and health sciencesAdvance Care Planning0302 clinical medicineMedicineHumans030212 general & internal medicineIntensive care medicineQualitative ResearchTerminal CareOncology (nursing)business.industryPalliative CareHematopoietic Stem Cell TransplantationUncertaintyGeneral Medicinemedicine.diseasePrognosisComorbidity3. Good health030228 respiratory systemOncologyCaregiversHematologic NeoplasmsInterdisciplinary CommunicationbusinessEnd-of-life careQualitative researchCurrent opinion in supportive and palliative care
researchProduct

Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.

2017

The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) proposed six Action Groups. After almost three years of activity, many achievements have been obtained through commitments or collaborative work of the Action Groups. However, they have often worked in silos and, consequently, synergies between Action Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the methodology and current status of the Task Force on EIP on AHA synergies. Synergies are in line with the Action Groups' new Renovated Action Plan (2016-2018) to ensure that their future objectives are coherent and fully connected. The …

AgingProcess managementGeriatrics & GerontologyEuropean Innovation Partnership on Active and Healthy Ageing polypharmacy education falls frailty integrated care citizen empowerment chronic respiratory diseasesHealth BehaviorChronic respiratory diseasesPARTNERSHIPCoaching[SHS]Humanities and Social Sciences0302 clinical medicineSurveys and Questionnaires80 and overMedicineCooperative BehaviorComputingMilieux_MISCELLANEOUSInterventionsmedia_commonintegrated careAged 80 and over:Enginyeria biomèdica [Àrees temàtiques de la UPC]Multiple Chronic ConditionOrganizational Innovation3. Good healthCHRONIC RESPIRATORY-DISEASESHealthAction planGeneral partnershipFallsHEALTHPartnershipINTERVENTIONSHumanmedia_common.quotation_subjectfallFrail ElderlyEuropean Continental Ancestry GroupBioengineeringWhite PeopleEducation03 medical and health sciencesEUROPEAN-UNIONActive and Healthy Ageingmedia_common.cataloged_instanceHumansBioenginyeriaEuropean unionAgedScience & TechnologyNutrition & DieteticsPreventionPREVENTIONCitizen empowerment030228 respiratory systemAction (philosophy)European Innovation Partnership on Active and Healthy Ageing; polypharmacy; education; falls; frailty; integrated care; citizen empowerment; chronic respiratory diseases; Accidental Falls; Aged; Aged 80 and over; Chronic Disease; Cooperative Behavior; Europe; Frail Elderly; Humans; Multiple Chronic Conditions; Organizational Innovation; Polypharmacy; Surveys and Questionnaires; Aging; European Continental Ancestry Group; Health BehaviorGeriatrics and GerontologyGerontologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]OPERATIONAL DEFINITIONEMPOWERMENTMedicine (miscellaneous)Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyChronic respiratory-diseasesAllergic rhinitisQUALITY-OF-LIFEEuropean-UnionNutrition and DieteticSurveys and Questionnaire030212 general & internal medicineMultiple Chronic ConditionsEmpowermenteducationNutrition and DieteticsFrailtyAccidental FallIntegrated careALLERGIC RHINITISEuropeSettore MED/42EmpowermentLife Sciences & BiomedicinefrailtyEuropean Innovation Partnership on Active and Healthy AgeingJournal ArticleMETIS-318216IR-101708Responsible Research and Innovationbusiness.industrychronic respiratory diseaseIntegrated careOperational definition3121 General medicine internal medicine and other clinical medicineChronic DiseasePolypharmacycitizen empowermentAccidental Fallschronic respiratory diseases; citizen empowerment; education; European Innovation Partnership on Active and Healthy Ageing; falls; frailty; integrated care; polypharmacy; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyQuality-of-lifebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe journal of nutrition, healthaging
researchProduct

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

2014

International audience; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patien…

AgingSettore MED/10 - Malattie dell'Apparato RespiratorioInternational CooperationRespiratory SystemMedically Underserved AreaComorbidityDiseaseEarly interventionMedical and Health Sciences[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractPulmonary Disease Chronic Obstructive0302 clinical medicineDisease controlRisk FactorsChronic obstructive lung diseaseHealth care030212 general & internal medicineRhinitimedia_commonRhinitisEnvironmental exposureChild health care3. Good healthALLERGIC RHINITISEuropeCHRONIC RESPIRATORY-DISEASESPERFORMANCE PROGRAMAction planSIMULATIONAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease; Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health OrganizationSMOKINGHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveChronic respiratory tract diseaseDecision MakingGuidelines as TopicDIAGNOSISWorld Health OrganizationOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease03 medical and health sciencesQuality of life (healthcare)EUROPEAN-UNIONmedicineMANAGEMENTmedia_common.cataloged_instanceHumansEuropean UnionEuropean unionIntensive care medicinebusiness.industryPublic healthRisk Factorta3121Respiration DisorderEnvironmental exposureRespiration DisordersAsthmaIntegrated care030228 respiratory systemPhysical therapyQuality of LifeClinical MedicineAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health Organizationbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySEVERE ASTHMA
researchProduct

Challenges in the pharmacological treatment of geriatric asthma

2016

ABSTRACTAsthma in older populations is characterized by frequent comorbid conditions, which increase the risk of side effects and of detrimental interactions between respiratory and non-respiratory drugs. These observations lead to the need to manage asthma in older populations by applying a multidimensional assessment and a multidisciplinary treatment; therefore, we favor the use of the ‘geriatric’ term to define asthma in the elderly. Geriatric asthma is a complex disease, which may not necessarily imply that it is also complicated, although the two conditions may often coexist. On this basis, the switch from an organ-driven management to the holistic approach may be the key factor to att…

Agingmedicine.medical_specialtyComplex diseaseComorbidityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentPharmacological treatmentOlder population03 medical and health sciences0302 clinical medicineMultidisciplinary approachAnimalsHumansMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicinePsychiatryAgedAsthmabusiness.industryAge FactorsGeneral Medicinemedicine.diseaseComorbidityAsthmaInhaled treatment030228 respiratory systemAdherencePharmacology Toxicology and Pharmaceutics (all)businessExpert Review of Clinical Pharmacology
researchProduct

Comorbidities of Lung Disease in the Elderly

2017

Comorbidities are common in elderly individuals with chronic respiratory diseases. They can affect disease manifestations and severity and can even impact management. Comorbidities can affect the treatment of the lung disease, particularly because of the interaction with the respiratory drugs. Thus, a multidimensional approach with multidisciplinary intervention is suggested for elderly respiratory patients, switching from a disease-oriented scheme to a dysfunction-oriented approach. Unfortunately, older individuals are often excluded from clinical trials because of advanced age and comorbidities. This article reviews the role of comorbidities in the management of respiratory diseases in th…

Agingmedicine.medical_specialtyRespiratory Tract DiseasesComorbidityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)03 medical and health sciences0302 clinical medicineIntervention (counseling)medicineHumansSenile lung030212 general & internal medicineRespiratory systemIdiopathic lung fibrosiIntensive care medicineRespiratory Tract DiseaseAgedAsthmabusiness.industryChronic obstructive pulmonary diseasefood and beveragesmedicine.diseaseComorbidityAsthmaPatient Care ManagementClinical trial030228 respiratory systemLung diseaseGeriatrics and GerontologybusinessHumanClinics in Geriatric Medicine
researchProduct

Perinatal exposure to 5-methoxytryptamine, behavioural-stress reactivity and functional response of 5-HT1A receptors in the adolescent rat.

2008

Abstract Serotonin is involved in a wide range of physiological and patho-physiological mechanisms. In particular, 5-HT1A receptors are proposed to mediate stress-adaptation. The aim of this research was to investigate in adolescent rats: first, the consequences of perinatal exposure to 5-metoxytryptamine (5MT), a 5-HT1/5-HT2 serotonergic agonist, on behavioural-stress reactivity in elevated plus maze, open field and forced swim tests; secondly, whether the behavioural effects induced by perinatal exposure to 5MT on open field and forced swim tests were affected by the selective 5-HT1A receptor agonist LY 228729, a compound able to elicit a characteristic set of motor behaviours on these ex…

AgonistMalemedicine.medical_specialtyElevated plus mazePerinatal 5MTOffspringmedicine.drug_classPyridinesPresynaptic TerminalsAnxietyMotor ActivitySerotonergicOpen fieldPiperazinesStatistics Nonparametric5-MethoxytryptamineBehavioral NeuroscienceSerotonin AgentsSex FactorsPregnancyBehavioural-stress reactivityInternal medicinemedicineAdolescent ratAnimals5-HT1A receptorErgolinesRats WistarAnalysis of VariancePerinatal 5MT; 5-HT1A receptors; Acute LY 228729 and WAY 100635; Behavioural-stress reactivity; Adolescent ratPerinatal ExposureBrainDrug SynergismRatsEndocrinologyAnimals NewbornPrenatal Exposure Delayed EffectsReceptor Serotonin 5-HT1ASynapsesSettore BIO/14 - FarmacologiaExploratory BehaviorAcute LY 228729 and WAY 100635FemaleSerotoninPsychologyStress PsychologicalBehavioural despair testBehavioural brain research
researchProduct

Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie – ein Positionspapier von ARIA, EAACI, AeDA, GPA und DGAKI (Kurzversion) – Positionspapier …

2020

Allergen immunotherapyCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemOtorhinolaryngologyDermatology clinicPandemicImmunologyPosition paperMedicinebusinessCoronavirus InfectionsLaryngo-Rhino-Otologie
researchProduct